

## **FREQUENCY EXCHANGE CORP. COMMENCES TRADING ON TSX VENTURE EXCHANGE UNDER “FREQ” FOLLOWING COMPLETION OF QUALIFYING TRANSACTION**

**VANCOUVER, BRITISH COLUMBIA – February 7, 2022 – Frequency Exchange Corp. (formerly, Israel Capital Canada Corp.) (the “Company”) (TSXV: FREQ)** is pleased to announce that its common shares began trading today on the TSX Venture Exchange under the symbol “FREQ”.

“This is an exciting day for all of us at the Company,” said CEO Stephen Davis. “We live in an age where frequencies are starting to get the recognition they deserve. Frequencies are used with great success in all types of applications and have been delivered in many forms throughout time. As Nikola Tesla, the Serbian American inventor and engineer who discovered and patented the rotating magnetic field, the basis of most alternating-current machinery, stated **“If you want to find the secrets of the universe, think in terms of energy, frequency and vibration.”** This is the world we find ourselves in and frequencies are having a positive impact. We are not only bringing hope to people struggling with health issues, we are providing them life changing results. Now we are funded and poised to enter the global stage as we introduce our wholly owned subsidiary **“Fremedica”** to the world -- a company which is having a positive impact on those struggling with symptoms of Lyme disease. This is the first of many frequency initiatives that we will explore as the Company moves forward.”

### **Qualifying Transaction and Shareholder Approval**

As previously announced on February 2, 2022, the Company completed its Qualifying Transaction (as such term is defined in TSX Venture Exchange (the **“Exchange”**) Policy 2.4 – *Capital Pool Companies* (**“Policy 2.4”**)) consisting of the acquisition by the Company of all of the issued and outstanding securities of FREmedica Technologies Inc. (**“FREmedica”**) in exchange for the issuance of securities of the Company to the securityholders of FREmedica under the terms of a Securities Exchange Agreement dated January 14, 2022 among the Company, FREmedica and the FREmedica securityholders (the **“Transaction”**).

The Company obtained written shareholder approval of a majority of disinterested shareholders (the **“Shareholder Approval”**) as the Transaction constituted a Non-Arm’s Length Qualifying Transaction (as such term is defined Policy 2.4) under the policies of the Exchange. Upon further consideration, the provisions of Multilateral Instrument 61-101 – *Protection of Minority Security Holders in Special Transactions* was not applicable to the Transaction as was disclosed in the Company’s filing statement dated January 17, 2022. The Company nonetheless relied on the Shareholder Approval to comply with the policies of the Exchange.

### **About the Company**

The Company is a British Columbia-based company focused on the development and commercialization of a frequency emitter that delivers a special package of frequencies designed for the health and wellness market, specifically to target Lyme disease within North America. The Wave 1 is the third generation frequency emitter released from the Company. It is the second wearable technology designed by the Company, specifically to deliver frequencies to help clients with chronic Lyme disease. The technology combined with the frequencies is the result of years of development and experimentation with the latest in bio-energetic technology.

For more information, please contact:

**Frequency Exchange Corp.**

Stephen Davis  
CEO & Director  
250-732-7170

**Cautionary Note Regarding Forward-Looking Information**

*Certain information contained herein constitutes “forward-looking information” under Canadian securities legislation. Forward-looking information includes, but is not limited to, statements with respect to the trading date of the Company’s common shares on the Exchange. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “will” or variations of such words and phrases or statements that certain actions, events or results “will” occur. Forward-looking statements are based on the opinions and estimates of management as of the date such statements are made and they are subject to known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on forward-looking statements and forward-looking information. The Company will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.*

*Additional information identifying risks and uncertainties is contained in filings by the Company with the Canadian securities regulators, which filings are available at [www.sedar.com](http://www.sedar.com).*

*Neither the Exchange nor its Regulation Services Provider (as that term is defined in policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.*